In terms of diagnosis, IDH1/2 genotyping is helpful in predicting the histological grade (2016 classification) and is now systematically used to make the distinction between GBM and non-GBM tumors (IDH-mutated grade 4 astrocytomas) in the recent classification1,9. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).